Companies › Umecrine Cognition
1 active drug program in 1 registered trial: 1 Phase 1; Gastroenterology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| golexanolone Positive allosteric modulator of GABA-A receptor | GABRA1 | Phase 1 | Primary Biliary Cholangitis (PBC) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07304843 | golexanolone | Phase 1 | Primary Biliary Cholangitis (PBC) | Gastroenterology | Sep 2026 |
Ono Pharmaceutical Seaport Therapeutics Lipocine UCB Biopharma SRL Haisco Pharmaceutical Group Neurodawn Pharmaceutical SK Life Science Sedana Medical Acacia Pharma
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.